<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005537</url>
  </required_header>
  <id_info>
    <org_study_id>2355.00</org_study_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>FHCRC-2355.00</secondary_id>
    <secondary_id>IR-6984</secondary_id>
    <secondary_id>CDR0000648071</secondary_id>
    <nct_id>NCT01005537</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Single Patient Study to Evaluate Cellular Adoptive Immunotherapy Using Autologous Lymphocytes Following Cyclophosphamide Conditioning for a Single Patient With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to&#xD;
      stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Biological therapy, such as cellular adoptive immunotherapy using autologous&#xD;
      lymphocytes, may stimulate the immune system in different ways and stop tumor cells from&#xD;
      growing. Aldesleukin may stimulate the lymphocytes to kill tumor cells. Giving&#xD;
      cyclophosphamide together with autologous lymphocytes and aldesleukin may be an effective&#xD;
      treatment for metastatic melanoma.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of giving cyclophosphamide&#xD;
      together with autologous lymphocytes and aldesleukin and to see how well it works in treating&#xD;
      patients with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess the safety and toxicity of cellular adoptive immunotherapy with autologous&#xD;
           tumor-infiltrating lymphocytes (TIL) following cyclophosphamide conditioning and&#xD;
           post-infusion aldesleukin (IL-2) in patients with metastatic melanoma.&#xD;
&#xD;
        -  Assess the duration of in vivo persistence of adoptively transferred lymphocytes.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the antitumor effect of adoptively transferred autologous TIL following&#xD;
           cyclophosphamide conditioning and post-infusion IL-2 in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive cyclophosphamide IV on days -3 and -2 and autologous&#xD;
      tumor-infiltrating lymphocytes (TIL) IV on day 0. Beginning 6 hours after TIL infusion,&#xD;
      patients receive high-dose aldesleukin (IL-2) IV three times daily on days 0-5 (for up to 14&#xD;
      doses) OR low-dose IL-2 subcutaneously twice daily on days 0-14 (for up to 28 doses).&#xD;
      Patients may then receive two additional courses of TILs and low-dose IL-2 (with or without&#xD;
      cyclophosphamide), if indicated.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <study_type>Expanded Access</study_type>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Given IV and orally</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
    <description>Given IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histopathological documentation of melanoma concurrent with the diagnosis of&#xD;
             metastatic disease.&#xD;
&#xD;
          -  18 to 75 years of age and able to tolerate high-dose cyclophosphamide&#xD;
&#xD;
          -  Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic&#xD;
             imaging (X-ray, CT scan).&#xD;
&#xD;
          -  For patients receiving HD-IL-2, normal cardiac stress test within 182 days prior to&#xD;
             enrollment is required of all patients over 50 years old or those with an abnormal&#xD;
             ECG, any history of cardiac disease, a family history of cardiac disease,&#xD;
             hypercholesterolemia or hypertension.&#xD;
&#xD;
          -  For leukapheresis, patients must meet the following criteria (any exceptions to this&#xD;
             will require prior approval by the Apheresis director and Principal Investigator):&#xD;
&#xD;
               -  Pulse: &gt;45 or &lt; 120&#xD;
&#xD;
               -  Weight: &gt;45 kg&#xD;
&#xD;
               -  Temperature: &lt;38C (&lt;100.4 F)&#xD;
&#xD;
               -  WBC: &gt;3,000&#xD;
&#xD;
               -  HCT: &gt;30%&#xD;
&#xD;
               -  Platelets: &gt;100,000&#xD;
&#xD;
          -  ADDITIONAL INCLUSION CRITERIA FOR T CELL INFUSION&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Significant cardiovascular abnormalities as defined by any one of the following:&#xD;
&#xD;
               -  congestive heart failure,&#xD;
&#xD;
               -  clinically significant hypotension,&#xD;
&#xD;
               -  symptoms of coronary artery disease,&#xD;
&#xD;
               -  presence of cardiac arrhythmias on EKG requiring drug therapy&#xD;
&#xD;
               -  ejection fraction &lt; 50 % (echocardiogram or MUGA)&#xD;
&#xD;
          -  Patients with active infections or oral temperature &gt; 38.2 C within 72 hours of study&#xD;
             entry or systemic infection requiring chronic maintenance or suppressive therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cassian Yee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>October 30, 2009</study_first_submitted>
  <study_first_submitted_qc>October 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2009</study_first_posted>
  <last_update_submitted>August 4, 2010</last_update_submitted>
  <last_update_submitted_qc>August 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Cassian Yee</name_title>
    <organization>Fred Hutchinson Cancer Research Center</organization>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

